We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 43% over five years while the S&P 500 rose 74%.
| Holding it back | A $35M loss |
| Latest filing | 8-K, Oct 28 |
After its last 4 reports it closed -6.1% on average, higher 2 of 4 times.
Poorfor quality, not price, 0 of 14 chart checks firingWhat the Quality Score means
CLPT is #76 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 76 |
Expected to report Wed Mar 17, after the close (in 133 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $12.1M, 36% more than a year ago; a loss of $0.24 a share, from $0.21.
“The acceleration of our financial performance in the third quarter was driven by our core organic clinical product revenue, as well as our biologics and drug delivery revenue both returning to double-digit growth.”
CLPT's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $48M to $50M |
“The increase is driven primarily by additional revenues due to sales of the IRRA flow product, which the Company acquired in connection with its acquisition of IRRAS in the fourth quarter of 2025.”
From its results filing (SEC filing · Oct 28)
Its share count grew 5.4% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Oct 28, 2026 | +2.8% | +1.2% | open |
| Aug 3, 2026 | -15.3% | -16.3% | -5.3% |
| May 13, 2026 | -2.3% | +4.8% | -8.1% |
Sales grew every year from 2018 to 2025, to $37M. It lost money in each of the eight years.
2 insiders sold $251K across 2 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CLPT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
“The medical device industry is highly competitive, subject to rapid technological change and significantly affected by new product introductions and market activities of other participants.”
CLPT scores -2 today, which Breakaway calls Poor. It is #76 of 85 in Medical Devices by Quality Score, with 0 of 14 chart checks firing. Down 43% over five years while the S&P 500 rose 74%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CLPT scores -2 today, which Breakaway calls Poor (below zero). That is #76 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CLPT's -2.
2 insiders sold $251K across 2 filings in the last 6 months. No open-market buys on record. The newest is Timothy T. Richards, Director, who sold $66K on Jun 1. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.